TABLE 1

Chemotherapy Response Monitoring in Advanced Colorectal Cancer

Authors	Year	Reference	No. of patients	Therapy	Timing of PET evaluation	PET response criteria	Outcome measures	Results	P
Findlay et al.	1996	10	18	5-FU chemotherapy	1–2 wk, 4–5 wk	−ΔT:L > 15% (at 4–5 wk)	Morphologic response on CT scan at 12 wk (WHO criteria)	Sensitivity 100%; specificity 75%
Bender et al.	1999	11	6	5-FU+FA chemotherapy	72 h	−ΔSUV	Morphologic response on CT scan at 6 wk (WHO criteria)	Responders −22%; nonresponders +13%	<0.01
Dimitrakopoulou-Strauss et al.	2003	12	28	FOLFOX chemotherapy	2 wk, 3 mo	SUV, FD	Morphologic response on CT scan at 12 wk (WHO criteria)	Correct classification rate: FD baseline PET 90% for PD; FD baseline PET 75% for SD
Dimitrakopoulou-Strauss et al.	2004	13	25	FOLFOX chemotherapy	2 wk, 8 wk	SUV, k₁–k₄, FD, VB	OS	Correct classification rate: SUV 62% at 2 wk and 69% at 8 wk; k₁–k₄, FD, and VB 78% at 2 and 8 wk
								OS–SUV correlation at 2 wk 0.426	0.035
								OS–SUV correlation at 8 wk 0.517	0.001
de Geus-Oei et al.	2007	14	50	Various chemotherapy schedules	2 mo, 6 mo	−ΔSUV, −ΔMR_glu	OS	−ΔSUV at 2 mo	0.017
								−ΔMR_glu at 2 mo	0.049
							Progression-free survival	−ΔSUV at 2 mo	0.035
								−ΔMR_glu at 2 mo	0.026

ΔT:L = fractional change in tumor-to-liver ratio; FA = folinic acid; ΔSUV = fractional change in SUV; FD = fractal dimension; PD = progressive disease; SD = stable disease; k₁–k₄ = rate constants; VB = vascular fraction; OS = overall survival; ΔMR_glu = fractional change in MR_glu.